CAR-T in R/R ALL: Case-Based Discussion of Lymphodepletion and Toxicity Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

CAR-T in R/R ALL: Case-Based Discussion of Lymphodepletion and Toxicity Management

By XV Eurasian Hematology-Oncology Congress - EHOC 2024 FEATURING Ebru Erdogan

12 views

August 30, 2024

Comments 0

Leukemia

Pediatric ALL: Etiology, Diagnosis and Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

O. TüFekçI GüRocak

14 views

CML Case Discussion: Elderly Patients not Meeting ELN Milestones

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Isam Sharif

7 views

New

CLL Case: Acquired Del(17p) at Relapse

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Özer Çerme

New

ALL Case: B-ALL Arising During Len Maintenance in Myeloma Patient

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Ozsoy

Novel Agents in the Treatment of R/R CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

41 views

Venetoclax-Based Regimens in AML: Understanding Resistance and Devel…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

93 views

Targeted Therapies in AML With a Focus on FLT3 Inhibitors

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

31 views

A Clinical Case of Extranodal MZL of the Palatum Durum After CLL/SLL…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Ridova

6 views

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

135 views

Ph+ ALL Management: Case-Based Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Koruk

15 views

AML Case Discussion: FLT3-ITD+ High-Risk Disease

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Hindilerden

20 views

Immunotherapy and Sequencing CD19-Targeted Therapies in Adults With …

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

37 views

How I Treat R/R CML in 2024: Strategies and Emerging Therapies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

19 views

TKI Discontinuation in CML: Defining Eligibility Criteria and Predic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Yassin

22 views

A Case of CMML With Recurrent Skin Involvement

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Arslan Davulcu

12 views

Critical Re-Evaluation of Established Practices in CML Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

151 views

Management of R/R AML: Treatment Options and Case Insights

XV Eurasian Hematology-Oncology Congress - EHOC 2024

V. Bonuomo

39 views

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

599 views

Practical Approach to MRD Monitoring in AML: Assessing Treatment Eff…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

96 views

Debates in Ph+ ALL: Allo-SCT Should Be Used Upfront in Adult Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Hoelzer

27 views

Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patie…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

37 views

CLL Case Discussion: First Line Treatment Strategies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Ortaboz

51 views

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

206 views